Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Designing opioids that deter abuse.

Raffa RB, Pergolizzi JV Jr, Muñiz E, Taylor R Jr, Pergolizzi J.

Pain Res Treat. 2012;2012:282981. doi: 10.1155/2012/282981. Epub 2012 Nov 8.

2.

Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.

Webster L.

Pain Med. 2009 Jul;10 Suppl 2:S124-33. doi: 10.1111/j.1526-4637.2009.00672.x. Review.

PMID:
19691683
3.

Non-analgesic effects of opioids: factors relevant to opioid abuse and abuse- deterrent formulations.

Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R.

Curr Pharm Des. 2012;18(37):6109-15. Review.

PMID:
22747546
4.

Opioid formulations in development designed to curtail abuse: who is the target?

Webster LR, Bath B, Medve RA.

Expert Opin Investig Drugs. 2009 Mar;18(3):255-63. doi: 10.1517/13543780902751622 . Review.

PMID:
19243277
5.

Opioids in headache treatment. Is there a role?

Ziegler DK.

Neurol Clin. 1997 Feb;15(1):199-207. Review.

PMID:
9058406
6.

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.

White AG, Birnbaum HG, Rothman DB, Katz N.

Appl Health Econ Health Policy. 2009;7(1):61-70. doi: 10.2165/00148365-200907010-00006.

PMID:
19558195
7.

College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.

Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sannerud C.

Drug Alcohol Depend. 2003 Apr 1;69(3):215-32. Review.

PMID:
12633908
8.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
9.

Development and validation of an Opioid Attractiveness Scale: a novel measure of the attractiveness of opioid products to potential abusers.

Butler SF, Benoit C, Budman SH, Fernandez KC, McCormick C, Venuti SW, Katz N.

Harm Reduct J. 2006 Feb 2;3:5.

10.

Abuse-deterrent opioid formulations: are they a pipe dream?

Katz N.

Curr Rheumatol Rep. 2008 Jan;10(1):11-8. Review.

PMID:
18457606
11.

The implications of tamper-resistant formulations for opioid rotation.

Pappagallo M, Sokolowska M.

Postgrad Med. 2012 Sep;124(5):101-9. doi: 10.3810/pgm.2012.09.2588.

PMID:
23095430
12.

Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond.

Ruan X.

Expert Opin Pharmacother. 2011 May;12(7):999-1001. doi: 10.1517/14656566.2011.571208. Epub 2011 Apr 7.

PMID:
21470064
13.

The burden of the nonmedical use of prescription opioid analgesics.

Gilson AM, Kreis PG.

Pain Med. 2009 Jul;10 Suppl 2:S89-100. doi: 10.1111/j.1526-4637.2009.00668.x. Review.

PMID:
19691688
14.

Development of opioid formulations with limited diversion and abuse potential.

Fudala PJ, Johnson RE.

Drug Alcohol Depend. 2006 Jun;83 Suppl 1:S40-7. Epub 2006 Mar 24.

PMID:
16564141
15.

Prescription opioid abuse in chronic pain: a review of opioid abuse predictors and strategies to curb opioid abuse.

Sehgal N, Manchikanti L, Smith HS.

Pain Physician. 2012 Jul;15(3 Suppl):ES67-92. Review.

16.

Estimating attractiveness for abuse of a not-yet-marketed "abuse-deterrent" prescription opioid formulation.

Butler SF, Black R, Grimes Serrano JM, Folensbee L, Chang A, Katz N.

Pain Med. 2010 Jan;11(1):81-91. doi: 10.1111/j.1526-4637.2009.00737.x. Epub 2009 Nov 25.

PMID:
20002324
17.

What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review.

Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS.

Pain Med. 2008 May-Jun;9(4):444-59. doi: 10.1111/j.1526-4637.2007.00370.x. Review.

PMID:
18489635
18.

Measuring attractiveness for abuse of prescription opioids.

Butler SF, Fernandez KC, Chang A, Benoit C, Morey LC, Black R, Katz N.

Pain Med. 2010 Jan;11(1):67-80. doi: 10.1111/j.1526-4637.2009.00736.x. Epub 2009 Nov 25.

PMID:
20002325
19.

Drug-abuse deterrent formulations.

Wick JY.

Consult Pharm. 2009 May;24(5):356-62, 365.

PMID:
19555144
20.

Clinical strategies for the primary health care professional to minimize prescription opioid abuse.

Gudin JA.

Postgrad Med. 2012 May;124(3):131-8. doi: 10.3810/pgm.2012.05.2556. Review.

PMID:
22691907

Supplemental Content

Support Center